Piper Sandler Begins Coverage of Bicara Therapeutics with an Overweight Rating
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 18 2025
0mins
Should l Buy BCAX?
Analyst Coverage: Piper Sandler analyst Kelsey Goodwin has begun coverage of Bicara Therapeutics.
Rating: The stock has been given an Overweight rating, indicating a positive outlook.
Price Target: A price target of $36 has been set for Bicara Therapeutics.
Market Implications: This rating and target suggest potential growth opportunities for investors in the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCAX
Wall Street analysts forecast BCAX stock price to rise
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 14.060
Low
11.00
Averages
30.80
High
48.00
Current: 14.060
Low
11.00
Averages
30.80
High
48.00
About BCAX
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bicara Therapeutics Reports Efficacy Data for 750mg Dose of Ficerafusp Alfa
- Efficacy Data Presentation: At the ESMO Asia Congress, Bicara Therapeutics presented preliminary data showing a 57% confirmed overall response rate for 750mg ficerafusp alfa combined with pembrolizumab, with 10% of patients achieving a complete response, indicating significant potential for treating HPV-negative recurrent/metastatic head and neck squamous cell carcinoma.
- Safety Analysis: The safety profile of the 750mg dose was consistent with the known safety of ficerafusp alfa plus pembrolizumab, demonstrating good tolerability in clinical applications and providing confidence for further research.
- Dose Optimization Plan: Bicara plans to declare the optimal biologic dose for the FORTIFI-HN01 study in the first quarter of 2026, further advancing clinical trial progress and aiming to accelerate the approval process for this therapy.
- TGF-β Inhibition Impact: Data from the 1500mg dose showed greater TGF-β inhibition, with a median depth of response of 82% compared to 63% for the 750mg dose, suggesting that higher doses may lead to more durable clinical outcomes, addressing the urgent need for effective treatments among patients.
See More
Bicara Therapeutics Reports 57% Response Rate for 750mg Ficerafusp Alfa in HNSCC Study
- Clinical Trial Progress: Bicara Therapeutics presented preliminary data at the ESMO Asia Congress showing a 57% confirmed overall response rate for 750mg Ficerafusp alfa combined with Pembrolizumab, with 10% of patients achieving a complete response, indicating significant potential in treating HPV-negative recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
- Dose Optimization Strategy: The data suggest that the 1500mg dose of Ficerafusp alfa achieves greater TGF-β inhibition in the tumor microenvironment, resulting in a median depth of response of 82%, compared to 63% for the 750mg dose, providing strong support for pursuing accelerated approval.
- Safety Analysis: The safety profile of 750mg Ficerafusp alfa in combination with Pembrolizumab was consistent with known safety data, demonstrating good tolerability and enhancing confidence in this treatment regimen.
- Future Outlook: Bicara plans to declare the optimal biologic dose for the FORTIFI-HN01 study in the first quarter of 2026, further advancing the clinical development of this therapy to meet the urgent market demand for effective treatment options.
See More
Bicara Reports Ficerafusp Alfa Clinical Data, 57% Response Rate at 750mg Dose
- Clinical Trial Progress: Bicara Therapeutics reports a 57% objective response rate for 750mg of ficerafusp alfa combined with pembrolizumab in the Phase 1b expansion cohort for 1L HPV-negative recurrent/metastatic head and neck squamous cell carcinoma, indicating significant therapeutic potential.
- Safety Analysis: The safety profile of this combination aligns with known characteristics of ficerafusp alfa and pembrolizumab, enhancing confidence in its clinical application and potentially accelerating FDA approval processes.
- Conference Presentation: Bicara will present these preliminary data at the European Society for Medical Oncology Congress on December 6, 2025, further elevating the company's visibility and influence in the biopharmaceutical sector.
- Market Demand: Given the treatment needs of head and neck squamous cell carcinoma patients, the development of ficerafusp alfa not only addresses a critical market gap but also has the potential to improve patient quality of life, meeting the growing demand for effective therapies.
See More
Reassessing Biotech Pipelines: The Valuation Indicator Investors Have Anticipated
Fair-Value Remeasurement Importance: Fair-value remeasurements under U.S. GAAP are becoming essential for late-stage biotech companies, providing insights into the financial implications of scientific advancements and enhancing shareholder value.
Oncotelic's Valuation Milestone: Oncotelic Therapeutics is set to undergo a significant fair-value remeasurement of its 45% stake in GMP Bio, with a new valuation indicating a potential asset value of approximately $765 million, reflecting progress in its oncology-focused pipeline.
Advancements in Clinical Programs: Oncotelic's pipeline includes multiple late-stage oncology and rare disease programs, with significant milestones achieved, such as advancements in OT-101 for pancreatic cancer and other promising candidates targeting various conditions.
Nanomedicine Market Growth: The valuation of Oncotelic's Deciparticle nanomedicine platform is tied to the growing market for nanomedicine, projected to exceed $350 billion by 2032, highlighting the potential for substantial financial recognition as clinical developments progress.
See More
Wells Fargo Keeps Equal-Weight Rating on Bicara Therapeutics and Increases Price Target to $11
- Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time market intelligence to help them make informed decisions.
- Exclusive Content: The platform features exclusive stories and insights generated by Benzinga reporters, catering to serious traders looking for an edge in the market.
- Community Engagement: Over 10,000 traders are part of the Benzinga Pro community, emphasizing the platform's popularity and reliability among serious market participants.
- Market Winning Strategy: The service is designed to help traders win in the markets every day by delivering timely and accurate stock market information.
See More
Bicara Therapeutics Reports Reduced Net Loss in Q3
- Q3 Financial Performance: Bicara Therapeutics (BCAX) reported a Q3 net loss of $0.67 per diluted share.
- Loss Comparison: The loss has narrowed compared to previous periods, indicating potential improvements in financial performance.
See More
Bicara Therapeutics Reports Efficacy Data for 750mg Dose of Ficerafusp Alfa
- Efficacy Data Presentation: At the ESMO Asia Congress, Bicara Therapeutics presented preliminary data showing a 57% confirmed overall response rate for 750mg ficerafusp alfa combined with pembrolizumab, with 10% of patients achieving a complete response, indicating significant potential for treating HPV-negative recurrent/metastatic head and neck squamous cell carcinoma.
- Safety Analysis: The safety profile of the 750mg dose was consistent with the known safety of ficerafusp alfa plus pembrolizumab, demonstrating good tolerability in clinical applications and providing confidence for further research.
- Dose Optimization Plan: Bicara plans to declare the optimal biologic dose for the FORTIFI-HN01 study in the first quarter of 2026, further advancing clinical trial progress and aiming to accelerate the approval process for this therapy.
- TGF-β Inhibition Impact: Data from the 1500mg dose showed greater TGF-β inhibition, with a median depth of response of 82% compared to 63% for the 750mg dose, suggesting that higher doses may lead to more durable clinical outcomes, addressing the urgent need for effective treatments among patients.
See More
Bicara Therapeutics Reports 57% Response Rate for 750mg Ficerafusp Alfa in HNSCC Study
- Clinical Trial Progress: Bicara Therapeutics presented preliminary data at the ESMO Asia Congress showing a 57% confirmed overall response rate for 750mg Ficerafusp alfa combined with Pembrolizumab, with 10% of patients achieving a complete response, indicating significant potential in treating HPV-negative recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
- Dose Optimization Strategy: The data suggest that the 1500mg dose of Ficerafusp alfa achieves greater TGF-β inhibition in the tumor microenvironment, resulting in a median depth of response of 82%, compared to 63% for the 750mg dose, providing strong support for pursuing accelerated approval.
- Safety Analysis: The safety profile of 750mg Ficerafusp alfa in combination with Pembrolizumab was consistent with known safety data, demonstrating good tolerability and enhancing confidence in this treatment regimen.
- Future Outlook: Bicara plans to declare the optimal biologic dose for the FORTIFI-HN01 study in the first quarter of 2026, further advancing the clinical development of this therapy to meet the urgent market demand for effective treatment options.
See More
Bicara Reports Ficerafusp Alfa Clinical Data, 57% Response Rate at 750mg Dose
- Clinical Trial Progress: Bicara Therapeutics reports a 57% objective response rate for 750mg of ficerafusp alfa combined with pembrolizumab in the Phase 1b expansion cohort for 1L HPV-negative recurrent/metastatic head and neck squamous cell carcinoma, indicating significant therapeutic potential.
- Safety Analysis: The safety profile of this combination aligns with known characteristics of ficerafusp alfa and pembrolizumab, enhancing confidence in its clinical application and potentially accelerating FDA approval processes.
- Conference Presentation: Bicara will present these preliminary data at the European Society for Medical Oncology Congress on December 6, 2025, further elevating the company's visibility and influence in the biopharmaceutical sector.
- Market Demand: Given the treatment needs of head and neck squamous cell carcinoma patients, the development of ficerafusp alfa not only addresses a critical market gap but also has the potential to improve patient quality of life, meeting the growing demand for effective therapies.
See More
Reassessing Biotech Pipelines: The Valuation Indicator Investors Have Anticipated
Fair-Value Remeasurement Importance: Fair-value remeasurements under U.S. GAAP are becoming essential for late-stage biotech companies, providing insights into the financial implications of scientific advancements and enhancing shareholder value.
Oncotelic's Valuation Milestone: Oncotelic Therapeutics is set to undergo a significant fair-value remeasurement of its 45% stake in GMP Bio, with a new valuation indicating a potential asset value of approximately $765 million, reflecting progress in its oncology-focused pipeline.
Advancements in Clinical Programs: Oncotelic's pipeline includes multiple late-stage oncology and rare disease programs, with significant milestones achieved, such as advancements in OT-101 for pancreatic cancer and other promising candidates targeting various conditions.
Nanomedicine Market Growth: The valuation of Oncotelic's Deciparticle nanomedicine platform is tied to the growing market for nanomedicine, projected to exceed $350 billion by 2032, highlighting the potential for substantial financial recognition as clinical developments progress.
See More
Wells Fargo Keeps Equal-Weight Rating on Bicara Therapeutics and Increases Price Target to $11
- Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time market intelligence to help them make informed decisions.
- Exclusive Content: The platform features exclusive stories and insights generated by Benzinga reporters, catering to serious traders looking for an edge in the market.
- Community Engagement: Over 10,000 traders are part of the Benzinga Pro community, emphasizing the platform's popularity and reliability among serious market participants.
- Market Winning Strategy: The service is designed to help traders win in the markets every day by delivering timely and accurate stock market information.
See More
Bicara Therapeutics Reports Reduced Net Loss in Q3
- Q3 Financial Performance: Bicara Therapeutics (BCAX) reported a Q3 net loss of $0.67 per diluted share.
- Loss Comparison: The loss has narrowed compared to previous periods, indicating potential improvements in financial performance.
See More
